The NaviFUS System developed by NaviFUS Corp. was a winner of the TIE Award during Taiwan Innotech Expo this year. The device plans to complete a multi-national Phase III clinical trial, so the company is seeking to cooperate with major pharmaceuticals companies worldwide in testing their drugs or acquiring funding to obtain a sales license from the Ministry of Health and Welfare. Furthermore, the equipment needs specialized semiconductor components and microprocessors to generate and receive ultrasound. Hence, the company is searching for industry partners to engage in joint R&D to make the equipment smaller, so that patients will not need to go to a hospital and can use the equipment in a clinic or even at home.
The NaviFUS® System, the Neuronavigation-guided focused ultrasound system developed by NaviFUS Corp., has completed a Phase II clinical trial in Taiwan for recurrent glioblastoma multiforme. Primary efficacy assessment data has shown promising results, and subsequently, the company plans to initiate a Phase III trial in Taiwan and a clinical trial in the United States. Additionally, it is exploring opportunities for international collaboration and patent sublicensing.
NaviFUS Corporation proudly announces its receipt of an Honorable Mention at the esteemed 2023 Tech Innovation Excellence Award (TIE Award), underscoring the groundbreaking impact of its Neuronavigation-Guided Focused Ultrasound (FUS) System. This recognition is in the competitive Semiconductors category, highlighting NaviFUS’ proficiency of integrating novel chip and circuit design theory in the FUS domain and establishing itself as a major force among seasoned veterans in Taiwan’s high-tech landscape.
NaviFUS and Bracco have recently made great progress towards an early-stage cooperation agreement that is expected to be finalized in the near future. Bracco’s microbubble products will be used together with NaviFUS’ NaviFUS system, which uses focused ultrasound to stimulate microbubbles to temporarily open the Blood-Brain-Barrier (BBB) and allow enhanced drug delivery.
Watch Now! Find out more about the latest updates at NaviFUS.
Presenters include Dr. Arthur Lung, CEO of NaviFUS, along with two leading clinicians, Dr. Kuo-Chen Wei and Dr. Hsiang-Yu Yu, to discuss their groundbreaking clinical projects using NaviFUS devices.
Dr. Wei is exploring the use of focused ultrasound for glioblastoma multiforme (GBM), a particularly aggressive form of brain cancer.
Dr. Yu is investigating the use of focused ultrasound for epilepsy by targeting specific areas of the brain.
The agreement will enable NaviFUS and Brainlab to explore the benefits of combining focused ultrasound and surgical guidance technologies.
NaviFUS (TaiEx: 6872) recently signed an earlystage cooperation agreement with Brainlab, a global leader in surgical imaging and navigation. The agreement will enable the companies to combine focused ultrasound (FUS) and surgical guidance technologies and identify methods that could accelerate the clinical integration of these approaches.
Dr. Yu Hsiang-Yu, Director of the Epilepsy Department at Taipei Veterans General Hospital Neurological Center, held a press conference earlier today summarizing the results of the previous pilot clinical trial using focused ultrasound (FUS) to treat patients with epilepsy and promoting the follow-up study that is currently underway.
NaviFUS Corporation (6872), an innovator of focused ultrasound technology announced that its NAVIRFA® Scope product has consecutively received approvals for the Sales License for Class II Medical Device from TFDA (Taiwan Food and Drug Administration) and the 510(K) Premarket Notification from US FDA in early May.
The “NaviFUS Focused Ultrasound System” developed by NaviFUS Corporation recently won Gold at the 2022 Edison Awards – Science & Medical Outpatient Treatment category on Apr. 22, 2022. Also competing in this category were other innovative products by renowned companies Abbott Laboratories and Spark Biomedical.
NaviFUS Corporation’s “Neuronavigation-guided Focused Ultrasound System” has recently been shortlisted for the 2022 Edison Award – Science & Medical Outpatient Treatment category – together with global pharmaceutical giant Abbott and Spark Medical Inc. (market value: US$4.4 billion). Final results for the gold, silver, and bronze medals will be announced in April in Florida, USA. The news is an affirmation that NaviFUS can compete side by side with other first-rate companies around the world, and Taiwan’s innovative talent is once again visible on the world stage.
